Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials

Figures

• 

  Fig. 1. Mean HbA1c values at randomization and at follow-up, in PARAGON-HF participants with diabetes, by treatment groups. Error bars represent 95% confidence intervals. P from mixed model for equality of HbA1c slopes

• 

  Fig. 2. Cumulative incidence of different outcomes in PARAGON-HF participants with diabetes. A New use of insulin. B New use of non-insulin antihyperglycemic medications. C Hypoglycemia. HR hazard ratio, CI confidence interval

• 

  Fig. 3. Treatment effects of sacubitril/valsartan compared with control treatment (valsartan in PARAGON-HF and enalapril in PARADIGM-HF) in patients with heart failure and diabetes, by left ventricular ejection fraction. A HbA1c reduction from randomization to 48 weeks (n = 5241). B New use of insulin (n = 4778). C New use of non-insulin antihyperglycemic medications (n = 2232). D Hypoglycemia (n = 6173)